The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

The ASX200 has been trading flat at around 8,280 points.

Mesoblast (ASX:MSB) has been the most watched on HotCopper so far today on news it’s received seven years of orphan-drug exclusive approval from the U.S. Food and Drug Administration.

Mesoblast has been $1.74.

WA1 Resources (ASX:WA1) has also been trending after Project Lumi’s assay results from resource definition drilling across the west of Luni achieved the best results to date.

WA1 Resources has been $12.28.

And, finally Anson Resources (ASX:ASN) has received the green light to commence a drilling program at its Green River Lithium Project (Project) in south-eastern Utah, USA.

Anson Resources has been 5.3 cents.

More From The Market Online
US flag

Dateline Resources pops +40% on Trump gov’t move to greenlight REE and gold mining

An injunction on ASX-listed Dateline Resources’ (ASX:DTR) California-based Colosseum REE and gold project appears set to be lifted after
The ASX Today feature image with a blue Australia silhouette (STOCK) beside The Market Link column branding.

ASX Today: XJO has a good day ahead of RBA rate call; AU bond sell-off continues

While we’re set to get the RBA’s next rate decision tomorrow – which all big bank analysts think is going to be a
Aussie cash

Northern Star jumps +7% on confirmed takeover rumour from Gold Fields Ltd

ASX-listed Northern Star Resources (ASX:NST) has confirmed reports in Bloomberg that it’s received a 100% takeover offer from a

AFT Pharmaceuticals opens Japan opportunity for Maxigesic IV

AFT Pharmaceuticals (ASX: AFP) has secured an exclusive development, licensing and supply agreement for its Maxigesic® IV (also known as Combogesic® IV)